Financial Survey: Spruce Biosciences (NASDAQ:SPRB) versus Actinium Pharmaceuticals (NYSE:ATNM)

Spruce Biosciences (NASDAQ:SPRB) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Institutional & Insider Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Spruce Biosciences and Actinium Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	2	4	0	2.43
Actinium Pharmaceuticals	0	0	2	0	3.00

Spruce Biosciences currently has a consensus target price of $203.25, indicating a potential upside of 276.32%. Actinium Pharmaceuticals has a consensus target price of $4.50, indicating a potential upside of 243.51%. Given Spruce Biosciences’ higher probable upside, research analysts clearly believe Spruce Biosciences is more favorable than Actinium Pharmaceuticals.

Volatility and Risk

Spruce Biosciences has a beta of 3.62, suggesting that its stock price is 262% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500.

Valuation & Earnings

This table compares Spruce Biosciences and Actinium Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91 million	15.07	-$38.97 million	($51.72)	-1.04
Actinium Pharmaceuticals	$90,000.00	456.68	-$48.82 million	($1.08)	-1.21

Spruce Biosciences has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Spruce Biosciences and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-203.99%	-127.96%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Spruce Biosciences beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.